Martin Shkreli

Martin Shkreli, born on March 17, 1983, is an American investor and businessman known for his controversial role in the pharmaceutical industry. He co-founded several hedge funds, including Elea Capital, MSMB Capital Management, and MSMB Healthcare. Additionally, he served as the co-founder and former CEO of pharmaceutical companies Retrophin and Turing Pharmaceuticals, as well as the former CEO of the software start-up Gödel Systems, which he established in August 2016.

Shkreli gained notoriety in September 2015 when Turing Pharmaceuticals acquired the manufacturing license for the antiparasitic drug Daraprim and raised its price from thirteen dollars and fifty cents to seven hundred fifty dollars per pill. This decision sparked widespread outrage and criticism, leading to his reputation as 'the most hated man in America.'

In 2017, Shkreli faced legal troubles when he was convicted in federal court on two counts of securities fraud and one count of conspiracy. He was sentenced to seven years in prison and ordered to pay fines totaling up to seven million four hundred thousand dollars. In a subsequent civil antitrust case, he was fined an additional sixty-four million six hundred thousand dollars to be repaid to victims.

After serving time, Shkreli was released early in May 2022 from a low-security federal prison in Allenwood, Pennsylvania. However, he remains permanently banned from serving as an officer of any publicly traded company.